Resistance to Direct Antiviral Agents for Hepatitis C Virus Infection: Impact on Clinical Practice?
Excerpt
Since the first generation protease inhibitors boceprevir & telaprevir were approved in combination therapy with peginterferon & ribavirin, we live in a time of outstanding revolution in hepatitis C virus infection [...]
Share and Cite
Pérez, A.B.; García, F. Resistance to Direct Antiviral Agents for Hepatitis C Virus Infection: Impact on Clinical Practice? GERMS 2016, 6, 123-124. https://doi.org/10.11599/germs.2016.1098
Pérez AB, García F. Resistance to Direct Antiviral Agents for Hepatitis C Virus Infection: Impact on Clinical Practice? GERMS. 2016; 6(4):123-124. https://doi.org/10.11599/germs.2016.1098
Chicago/Turabian StylePérez, Ana Belén, and Federico García. 2016. "Resistance to Direct Antiviral Agents for Hepatitis C Virus Infection: Impact on Clinical Practice?" GERMS 6, no. 4: 123-124. https://doi.org/10.11599/germs.2016.1098
APA StylePérez, A. B., & García, F. (2016). Resistance to Direct Antiviral Agents for Hepatitis C Virus Infection: Impact on Clinical Practice? GERMS, 6(4), 123-124. https://doi.org/10.11599/germs.2016.1098